/GYRE
GYRE Stock - Gyre Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$7.13-2.99%
$0.22 (-2.99%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.17
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+124.4%upside
Target: $16.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GYRE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.06 – $7.20
TARGET (TP)$16.00
STOP LOSS$6.56
RISK/REWARD1:15.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta7.07
52W High$14.42
52W Low$6.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $105.76M | $113.45M | $102.29M | $7.34M | $20.95M |
| Gross Profit | $101.87M | $108.81M | $97.50M | $-332,000 | $11.79M |
| Gross Margin | 96.3% | 95.9% | 95.3% | -4.5% | 56.3% |
| Operating Income | $16.16M | $-67,230,000 | $9.20M | $-83,726,000 | $-57,370,000 |
| Net Income | $12.09M | $-92,933,000 | $2.30M | $-87,933,000 | $-55,542,000 |
| Net Margin | 11.4% | -81.9% | 2.3% | -1198.3% | -265.1% |
| EPS | $0.14 | $-1.41 | $0.03 | $-2.87 | $-2.93 |
Company Overview
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 138.4% Upside
Now
$16
Low
$17
Average
$18
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 10th 2025 | Jefferies | Initiation | Buy | $16 |
| August 26th 2025 | H.C. Wainwright | Initiation | Buy | $18 |
| March 11th 2025 | Noble Capital Markets | Initiation | Outperform | - |
Earnings History & Surprises
GYREBeat Rate
50%
Last 12 quarters
Avg Surprise
+29.8%
EPS vs Estimate
Beats / Misses
6/4
2 met exactly
Latest EPS
$0.06
Q4 2025
EPS Surprise History
Q1 24
-13.6%
$-0.68vs$-0.60
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
-75.0%
$0.01vs$0.04
Q2 25
0.0%
$0.03vs$0.03
Q3 25
-33.3%
$0.02vs$0.03
Q4 25
+20.0%
$0.06vs$0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $0.08 | — | — | — |
Q4 2025 | Nov 7, 2025 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $0.03 | $0.02 | -33.3% | ✗ MISS |
Q2 2025 | May 9, 2025 | $0.03 | $0.03 | 0.0% | = MET |
Q1 2025 | Mar 17, 2025 | $0.04 | $0.01 | -75.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | — | $0.02 | — | — |
Q3 2024 | Aug 13, 2024 | — | $0.01 | — | — |
Q2 2024 | May 9, 2024 | — | $0.04 | — | — |
Q1 2024 | Mar 26, 2024 | $-0.60 | $-0.68 | -13.6% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-0.75 | $-1.05 | -40.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.07 | $-0.07 | 0.0% | = MET |
Q2 2023 | May 15, 2023 | $-1.05 | $0.14 | +113.5% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-1.57 | $-0.05 | +96.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-1.50 | $-0.05 | +96.4% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-3.67 | $0.08 | +102.1% | ✓ BEAT |
Q2 2022 | May 9, 2022 | — | $0.08 | — | — |
Q1 2022 | Mar 31, 2022 | $-6.85 | $-0.65 | +90.6% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | — | $-0.80 | — | — |
Q3 2021 | Aug 5, 2021 | — | $-0.64 | — | — |
Q2 2021 | May 6, 2021 | — | $-0.79 | — | — |
Latest News
Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate
📈 PositiveBenzinga•Nov 7, 2025, 11:07 AM
Gyre Therapeutics shares are trading higher after the company announced it completed patient enrollment in the Phase 3 clinical trial of Pirfenidone capsules, for the treatment of pneumoconiosis.
📈 PositiveBenzinga•Oct 15, 2025, 03:57 PM
Gyre Therapeutics Has Completed Patient Enrollment In The 52-week Phase 3 Trial In China Of Pirfenidone Capsules, For Pneumoconiosis
📈 PositiveBenzinga•Oct 15, 2025, 11:05 AM
Gyre Therapeutics to Present Phase 3 Liver Fibrosis Trial Results at AASLD 2025
➖ NeutralBenzinga•Oct 14, 2025, 11:18 AM
Gyre Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $16 price target.
📈 PositiveBenzinga•Oct 10, 2025, 01:19 PM•Also:
Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16
📈 PositiveBenzinga•Oct 10, 2025, 11:28 AM•Also:
HC Wainwright & Co. Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $18
📈 PositiveBenzinga•Aug 26, 2025, 11:27 AM
Gyre Therapeutics slumps 16%, prices $20M stock offering
📉 NegativeSeeking Alpha•May 23, 2025, 07:35 AM
Frequently Asked Questions about GYRE
What is GYRE's current stock price?
Gyre Therapeutics, Inc. (GYRE) is currently trading at $7.13 per share. The stock has moved -2.99% today.
What is the analyst price target for GYRE?
The average analyst price target for GYRE is $16.00, based on 1 analyst.
What sector is Gyre Therapeutics, Inc. in?
Gyre Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GYRE's market cap?
Gyre Therapeutics, Inc. has a market capitalization of $0.65 billion, making it a small-cap company.
Does GYRE pay dividends?
No, Gyre Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
AVXL
Anavex Life Sciences Corp.
$3.67
Mkt Cap: $0.3B
CTMX
CytomX Therapeutics, Inc.
$4.00
Mkt Cap: $0.7B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
KROS
Keros Therapeutics, Inc.
$20.26
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
Explore stocks similar to GYRE for comparison